查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918115

阿片类药物使用疾患治疗市场－2026-2031年预测

Opioid Use Disorder Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

阿片类药物使用障碍治疗市场预计将从 2025 年的 75.88 亿美元成长到 2031 年的 115.45 亿美元，复合年增长率为 7.25%。

由于阿片类药物成瘾带来的临床和社会负担日益加重，包括强迫性使用、高復发风险和潜在的致命过量用药，阿片类药物使用障碍（OUD）治疗市场正在稳步扩张。药物辅助治疗（MOUD）－包括美沙酮、Buprenornhine和纳曲酮－是实证治疗的基础，而行为咨商和同侪支持模式则作为重要的辅助手段，有助于提高治疗依从性和改善长期治疗效果。

关键需求驱动因素源自于阿片类药物在治疗癌症、心血管疾病、整形外科疾病、术后復健和创伤等引起的慢性疼痛方面的广泛医疗用途。即使临床上确有指征，长期用药也往往会导致成瘾，并在减重或停药后出现戒断综合征，从而维持着庞大且不断增长的患者群体。

美国的结构性改革预计将显着扩大药物辅助治疗（MOUD）的覆盖范围，从而在整个预测期内加速市场成长。 DATA-2000豁免条款的废除以及Buprenornhine处方患者人数限制的取消，消除了长期存在的障碍，使更多医疗保健专业人员能够启动和维持治疗。联邦医疗保险（Medicare）和各州医疗补助计划（Medicaid）扩大了对综合阿片类药物治疗项目（OTP）的覆盖范围——对包括美沙酮给药、中毒检测、护理和咨询在内的综合服务（代码H0020）进行报销——进一步降低了经济障碍。值得注意的是，医疗补助计划已经涵盖了美国约40%非老年鸦片类药物使用障碍（OUD）患者的治疗费用。

实证心理社会介入措施的整合仍在不断发展中。戒毒互助会、酒精成瘾、动机增强疗法和结构化咨询正越来越多地被纳入住院和门诊治疗方案中，以帮助患者重新评估其阿片类药物使用情况，加强復发预防技能，并建立以康復为导向的行为模式。

由于慢性疼痛疾病的高发生率、恶性及非恶性疼痛的阿片类药物处方率高，以及主要生产商在北美地区的集中商业性，预计北美将继续保持其市场领先地位。像Indivior这样的公司的大部分收入都来自美国市场，这反映了该地区沉重的疾病负担和有利的报销趋势。

创新持续聚焦于研发能提高病患依从性、减少非法分销并简化给药方式的製剂。 2023年5月，一项具有里程碑意义的监管进展出现：美国食品药物管理局（FDA）批准了BRIXADI（Buprenornhine）的修订版新药申请。 BRIXADI是一种Buprenornhine缓释皮下注射（每週一次或每月一次），用于治疗中度至重度鸦片类药物使用疾患（OUD）。长效Buprenornhine注射剂的核准和即将上市核准将代表治疗模式的转变，尤其对于那些难以坚持口服药物的患者群体而言。

竞争的焦点在于下一代药物递送系统、联合药物疗法以及用于增强行为矫正的数位化治疗辅助。包括Braeburn Pharmaceuticals在内的领先研发企业正持续开发候选药物，以满足诱导期、稳定期和维持期尚未满足的医疗需求。

总之，在不可逆转的放鬆管制、公共医疗保险对阿片类药物治疗项目的全面覆盖以及医疗用阿片类药物暴露带来的持续临床需求的推动下，阿片类药物使用障碍（OUD）治疗领域正蓄势待发，准备持续扩张。北美在市场规模和治疗创新方面继续保持主导，而像BRIXADI这样的长效注射用Buprenornhine製剂代表了近期最显着的进展，为中重度阿片类药物使用障碍患者提供了更多安全、有效且易于获得的药物辅助治疗（MOUD）选择。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 依治疗方法的鸦片类药物使用障碍治疗市场

  • 介绍
  • 药物治疗
    • Buprenornhine
    • 美沙酮
    • 纳曲酮
  • 咨商与行为疗法

6. 依给药途径分類的鸦片类药物使用障碍治疗市场

  • 介绍
  • 口服
  • 注射

7. 按最终用户分類的阿片类药物使用障碍治疗市场

  • 介绍
  • 復健中心
  • 专科诊所
  • 其他的

8. 按地区分類的鸦片类药物使用障碍治疗市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Indivior Plc
  • Alkermes Plc
  • Orexo AB
  • Titan Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Camurus
  • Collegium Pharmaceuticals

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615587

The opioid use disorder treatment market, at a 7.25% CAGR, is anticipated to reach USD 11.545 billion in 2031 from USD 7.588 billion in 2025.

The opioid use disorder (OUD) treatment market is expanding steadily, propelled by the escalating clinical and societal burden of opioid dependence characterized by compulsive use, high relapse risk, and potential for fatal overdose. Medication for opioid use disorder (MOUD) - methadone, buprenorphine, and naltrexone - constitutes the evidence-based foundation of therapy, with behavioral counseling and peer-support models serving as critical adjuncts that improve retention and long-term outcomes.

Primary demand drivers remain rooted in the widespread medical use of opioids for chronic pain associated with cancer, cardiovascular disease, orthopedic conditions, post-surgical recovery, and trauma. Prolonged exposure, even when clinically indicated, frequently transitions legitimate prescribing into dependence and withdrawal syndromes upon dose reduction or cessation, sustaining a large and growing treatment-eligible population.

Structural reforms in the United States have significantly broadened access to MOUD and are expected to accelerate market growth throughout the forecast period. The elimination of the DATA-2000 waiver and removal of patient caps on buprenorphine prescribing have removed longstanding barriers, enabling a far wider range of practitioners to initiate and maintain therapy. Expanded Medicare and state Medicaid coverage of comprehensive opioid treatment programs (OTPs) - reimbursed through bundled services under code H0020 that include methadone administration, toxicology screening, nursing, and counseling - further lowers financial hurdles. Notably, Medicaid already finances care for approximately 40% of non-elderly adults with OUD in the U.S.

Integration of evidence-based psychosocial interventions continues to gain traction. Narcotics Anonymous, Alcoholics Anonymous, motivational enhancement, and structured counseling are increasingly embedded within inpatient and outpatient programs, helping patients reframe opioid use, strengthen relapse-prevention skills, and build recovery-oriented behavioral repertoires.

North America is projected to maintain clear market leadership, driven by high prevalence of chronic pain conditions, elevated rates of opioid prescribing for both malignant and non-malignant pain, and concentrated commercial presence of major manufacturers. Companies such as Indivior derive the majority of revenue from the U.S. market, reflecting both disease burden and favorable reimbursement dynamics.

Innovation remains focused on formulations that enhance adherence, reduce diversion, and simplify administration. A landmark regulatory advancement occurred in May 2023 when the FDA accepted Braeburn's revised New Drug Application for BRIXADI (buprenorphine) extended-release subcutaneous injection (weekly and monthly dosing) for moderate to severe OUD. Approval and subsequent launch of long-acting injectable buprenorphine formulations are anticipated to shift treatment paradigms, particularly in populations with poor oral medication adherence.

Competitive activity centers on next-generation delivery systems, combination pharmacotherapies, and digital therapeutic adjuncts designed to reinforce behavioral change. Leading developers, including Braeburn Pharmaceuticals, continue to advance candidates that address unmet needs in induction, stabilization, and maintenance phases.

In conclusion, the OUD treatment sector is poised for sustained expansion, supported by irreversible regulatory liberalization, comprehensive public insurance coverage of OTP services, and persistent clinical need generated by medical opioid exposure. North America will continue to dominate both in market size and therapeutic innovation, with long-acting injectable buprenorphine formulations such as BRIXADI representing the most significant recent advancement in expanding safe, effective, and accessible MOUD options for patients with moderate to severe opioid use disorder.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Opioid Use Disorder Treatment Market Segmentation:

BY TREATMENT TYPE

  • Medication
  • Buprenorphine
  • Methadone
  • Naltrexone
  • Counseling & Behavioral Therapies

BY ROUTE OF ADMINISTRATION

  • Oral
  • Injectable

BY END-USER

  • Rehabilitation Centers
  • Specialized Clinics
  • Others

BY GEOGRAPHY

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. OPIOID USE DISORDER TREATMENT MARKET BY TREATMENT TYPE

  • 5.1. Introduction
  • 5.2. Medication
    • 5.2.1. Buprenorphine
    • 5.2.2. Methadone
    • 5.2.3. Naltrexone
  • 5.3. Counseling & Behavioral Therapies

6. OPIOID USE DISORDER TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injectable

7. OPIOID USE DISORDER TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Rehabilitation Centers
  • 7.3. Specialized Clinics
  • 7.4. Others

8. OPIOID USE DISORDER TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Indivior Plc
  • 10.2. Alkermes Plc
  • 10.3. Orexo AB
  • 10.4. Titan Pharmaceuticals Inc.
  • 10.5. Teva Pharmaceutical Industries Ltd.
  • 10.6. Mallinckrodt Pharmaceuticals
  • 10.7. Pfizer Inc.
  • 10.8. Hikma Pharmaceuticals PLC
  • 10.9. Camurus
  • 10.10. Collegium Pharmaceuticals

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations